ADAM 17 selectively activates the IL ‐6 trans‐signaling/ ERK MAPK axis in KRAS ‐addicted lung cancer
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Oncogenic KRAS mutations are major drivers of lung adenocarcinoma (LAC), yet the direct therapeutic targeting of KRAS has been problematic. Here, we reveal an obligate requirement by oncogenic KRAS for the ADAM17 protease in LAC. In genetically engineered and xenograft (human cell line and patient‐derived) KrasG12D‐driven LAC models, the specific blockade of ADAM17, including with a non‐toxic prodomain inhibitor, suppressed tumor burden by reducing cellular proliferation. The pro‐tumorigenic activity of ADAM17 was dependent upon its threonine phosphorylation by p38 MAPK, along with the preferential shedding of the ADAM17 substrate, IL‐6R, to release soluble IL‐6R that drives IL‐6 trans‐signaling via the ERK1/2 MAPK pathway. The requirement for ADAM17 in KrasG12D‐driven LAC was independent of bone marrow‐derived immune cells. Furthermore, in KRAS mutant human LAC, there was a significant positive correlation between augmented phospho‐ADAM17 levels, observed primarily in epithelial rather than immune cells, and activation of ERK and p38 MAPK pathways. Collectively, these findings identify ADAM17 as a druggable target for oncogenic KRAS‐driven LAC and provide the rationale to employ ADAM17‐based therapeutic strategies for targeting KRAS mutant cancers. Oncogenic KRAS mutations are associated with one‐third of lung adenocarcinoma (LAC) cases, yet the downstream molecular events that facilitate KRAS‐mediated tumorigenesis in the lung remain unresolved. This study reveals an obligate requirement by oncogenic KRAS for the ADAM17 protease in LAC. Oncogenic KRAS mutations are associated with one‐third of lung adenocarcinoma (LAC) cases, yet the downstream molecular events that facilitate KRAS‐mediated tumorigenesis in the lung remain unresolved. This study reveals an obligate requirement by oncogenic KRAS for the ADAM17 protease in LAC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improving Bioscience Research Reporting: The ARRIVE Guidelines for Reporting Animal Research
Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M., & Altman, D. G. (2010) · PLoS Biology · doi:10.1371/journal.pbio.1000412 · Cited by 7,300
Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research
Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M., & Altman, D. G. (2010) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.4103/0976-500x.72351 · Cited by 6,277
The pro- and anti-inflammatory properties of the cytokine interleukin-6
Scheller, J., Chalaris, A., Schmidt-Arras, D., & Rose-John, S. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.01.034 · Cited by 3,212 · cited 1×
“…the opposing roles of IL-6 in either maintaining homeostatic processes (e.g., regulation of B-cell function, the acute phase response, and hematopoiesis), or conversely, driving chronic disease states such as inflammation and cancer (Scheller et al, 2011; Mihara et al, 2012; Jones & Jenkins, 2018).”
BackgroundSelf-citationIL-6 as a keystone cytokine in health and disease
Hunter, C. A., & Jones, S. A. (2015) · Nature Immunology · doi:10.1038/ni.3153 · Cited by 2,511 · cited 1×
“14 of 19 EMBO Molecular Medicine 11: e9976 | 2019 ª 2019 The Authors are facilitated by classic signaling, while the disease-associated functions of IL-6 primarily (or even exclusively) reside with transsignaling (Hunter & Jones, 2015; Jones & Jenkins, 2018).”
BackgroundA Comprehensive Survey of Ras Mutations in Cancer
Prior, I. A., Lewis, P. D., & Mattos, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2612 · Cited by 2,063 · cited 1×
“Activating point mutations in KRAS are among the most prevalent genetic alterations in cancer, with highest incidences specific for certain epithelial (e.g., lung, pancreatic, and colorectal) and hematological (e.g., acute myeloid leukemia and multiple myeloma) malignancies (Prior et al, 2012).”
BackgroundDrugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997
Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor
Janes, M. R., Zhang, J., Li, L.-S., Hansen, R., Peters, U., Guo, X., Chen, Y., Babbar, A., Firdaus, S. J., Darjania, L., et al. (2018) · Cell · doi:10.1016/j.cell.2018.01.006 · Cited by 1,172 · cited 1×
“…reports has described a new generation of SMIs that trap mutant KRAS (G12C) in a GDP-bound inactive state, with one compound in particular (ARS-1620) displaying robust anti-tumor activity in numerous NSCLC xenograft models harboring the KRASG12C allele (Patricelli et al, 2016; Janes et al, 2018).”
BackgroundRecent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer
Jones, S. A., & Jenkins, B. J. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0066-7 · Cited by 1,102
Self-citationDong, Z.-Y., Zhong, W.-Z., Zhang, X.-C., Su, J., Xie, Z., Liu, S.-Y., Tu, H.-Y., Chen, H.-J., Sun, Y.-L., Zhou, Q., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2554 · Cited by 959 · cited 1×
“…of malignancy, and prediction of response and/ or acquired resistance to both chemotherapy and targeted therapies against EGFR (i.e., TKIs) and, very recently, PD-L1-based checkpoint inhibition (Hames et al, 2016; Dong et al, 2017; Hirsch et al, 2017; Zhuang et al, 2017; Román et al, 2018).”
Background
Cited by
The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology
Rutsch, A., Kantsjö, J. B., & Ronchi, F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.604179 · Cited by 821
Diversity and versatility of p38 kinase signalling in health and disease
Canovas, B., & Nebreda, A. R. (2021) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-00322-w · Cited by 657
Targeting IL-6 trans-signalling: past, present and future prospects
Rose-John, S., Jenkins, B. J., Garbers, C., Moll, J. M., & Scheller, J. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-023-00856-y · Cited by 524
Self-citationRecent advances in mass spectrometry based clinical proteomics: applications to cancer research
Macklin, A., Khan, S., & Kislinger, T. (2020) · Clinical Proteomics · doi:10.1186/s12014-020-09283-w · Cited by 317
Non‐alcoholic fatty liver disease: a review of epidemiology, risk factors, diagnosis and management
Huang, T. (., Behary, J., & Zekry, A. (2020) · Internal Medicine Journal · doi:10.1111/imj.14709 · Cited by 227
Metadata
- Authors
- Saad, M. I., Alhayyani, S., McLeod, L., Yu, L., Alanazi, M., Deswaerte, V., Tang, K., Jarde, T., Smith, J. A., Prodanovic, Z., Tate, M. D., Balic, J. J., Watkins, D. N., Cain, J. E., Bozinovski, S., Algar, E., Kohmoto, T., Ebi, H., Ferlin, W., Garbers, C., Ruwanpura, S., Sagi, I., Rose‐John, S., & Jenkins, B. J.
- Venue
- EMBO Molecular Medicine
- Published
- 2019-03-04
- Volume
- 11
- Issue
- 4
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- OpenAlex
- W2920126503
- Cited by
- 136
- References
- 17
- FWCI
- 6.66
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: ADAM 17 selectively activates the IL ‐6 trans‐signaling/ ERK MAPK axis in KRAS ‐addicted lung cancer. https://app.cochat.ai/papers/10.15252/emmm.201809976
- The paper
- Saad, M. I., Alhayyani, S., McLeod, L., Yu, L., Alanazi, M., Deswaerte, V., Tang, K., Jarde, T., Smith, J. A., Prodanovic, Z., Tate, M. D., Balic, J. J., Watkins, D. N., Cain, J. E., Bozinovski, S., Algar, E., Kohmoto, T., Ebi, H., Ferlin, W., . . . Jenkins, B. J. (2019). ADAM 17 selectively activates the IL ‐6 trans‐signaling/ ERK MAPK axis in KRAS ‐addicted lung cancer. EMBO Molecular Medicine. https://doi.org/10.15252/emmm.201809976
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.